Company Overview and News

0
Sterling director Nitin Sandesara, held in Rs 5k-cr fraud case

2018-08-17 freepressjournal.in
New Delhi : Nitin Sandesara, an absconding director of a Gujarat-based pharma company which is being probed in a Rs 5,000 crore fraud case, has been arrested in Dubai, officials said. Officials said Sandesara was arrested by Dubai police based on a non-bailable arrest warrant issued by an Indian court.
532418 ANDHRABANK

0
Andhra Bank raises MCLR by 0.15% for various tenors

2018-08-16 moneycontrol
State owned Andhra Bank has increased the marginal cost of funds based lending rate (MCLR) by 0.15 per cent to up to 8.70 per cent for various tenors. "The bank has increased its MCLR with effect from August 16, 2018," Andhra Bank said in a BSE filing.
532418 ANDHRABANK

0
Andhra Bank - Updates

2018-08-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532418 ANDHRABANK

0
Accused in Rs 5,000 crore bank fraud case held in Dubai

2018-08-15 moneycontrol
Nitin Sandesara, an absconding director of a Gujarat-based pharma company which is being probed in a Rs 5,000 crore fraud case, has been arrested in Dubai, officials said. Officials said Sandesara was arrested by Dubai police based on a non-bailable arrest warrant issued by an Indian court.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
Andhra Bank - Investor Presentation

2018-08-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532418 ANDHRABANK

0
Vacant posts in top management of state-run banks likely to be filled by month-end

2018-08-14 livemint
New Delhi/Mumbai: The vacant posts in the top management of state-run banks are likely to be filled by the end of this month after clearance is received from the Central Vigilance Commission, a senior finance ministry official said on condition of anonymity.
INDIANB ALBK 532418 532814 CNRYY SYNDIBANK 532276 PNJZY 532121 532483 532461 532480 PNB CANBK DENABANK ANDHRABANK

1
Andhra Bank shares plummet nearly 5%

2018-08-13 thehindubusinessline
Shares of Andhra Bank touched its lowest in over 2 weeks. The stock plummeted as much as 4.85 per cent to Rs 32.40. - The Hindu
HDB 500180 532418 HDFCBANK CLNDY 533278 COALINDIA ANDHRABANK SBAZ

0
Andhra Bank - Change in Company Secretary/Compliance Officer

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532418 ANDHRABANK

0
SBI, NHPC, Hindalco, Sun TV, PC Jeweller, results

2018-08-09 thehindubusinessline
Andhra Bank, Apollo Hospitals, Allcargo Logistics, Bosch, DLF, Dr Lal Path, Deep Industries, GAIL, GE Shipping, Glenmark Pharma, Hindalco, Indian Hotels, JB Chemicals, Kirloskar Oil, Max India, Max Ventures, NCC, NHPC, PC Jeweller, Puravankara, STCI, State Bank of India, Sun TV, Shalimar Paints, Uflex, Union Bank of India, UCO Bank, United Breweries, Vakrangee, Voltas and Wanbury are among over 180 companies that will declare their April-June results on Friday.
UBNC SHALPAINTS UBL 532749 UBHOLDINGS 532418 532505 UNBWY 532478 DEEPIND 500271 532760 ALLCARGO 500850 534809 MAX PCJEWELLER UCOBANK INDHOTEL 507458 509874 MXGQY ANDHRABANK SBAZ

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...